Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Evaluation of an AI Agent-Assisted Proactive Postdischarge Management Model for Patients With Decompensated Cirrhosis

NCT07931404 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.

NCT NCT07931404 Not yet recruiting Not applicable 180 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07931404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, 180 participants (estimated). Lead sponsor Beijing Tsinghua Chang Gung Hospital; China. Primary measure: Proportion of Participants With a First Liver-Related Unplanned Acute Healthcare Utilization Event Within...

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Evaluation of an AI Agent-Assisted Proactive Postdischarge Management Model for Patients With Decompensated Cirrhosis
Lead sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
February 29, 2028
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them.

decompensated liver cirrhosis

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Beijing Tsinghua Chang Gung Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
AI Agent-Assisted Proactive Management Plus Standard Care Experimental AI Agent-Assisted Proactive Management, Standard Care
Show registry wording

Participants will receive standard care plus 90 days of AI agent-assisted proactive management after discharge. Participants or authorized caregivers will submit brief daily health reports and may report symptoms as they occur. The service combines AI-supported information structuring, rules-based risk alerts, nurse verification, physician-led clinical decisions, and documentation of actions and follow-up.

Standard Care Active comparator Standard Care
Show registry wording

Participants will receive standard care without access to the study AI agent-assisted proactive management service. Existing outpatient care, telephone follow-up, clinical contact channels, and access to emergency care will be maintained. Scheduled study outcome ascertainment and safety follow-up will be performed at the same frequency as in the experimental group.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Proportion of Participants With a First Liver-Related Unplanned Acute Healthcare Utilization Event Within 90 Days From discharge following the index hospitalization (Day 0) through Day 90.
Show registry wording

Proportion of participants with at least one unplanned emergency department visit, hospital observation stay, acute day-case treatment, or readmission due to acute deterioration of liver disease within 90 days after index-hospital discharge. Contacts arising from the same episode of deterioration count as one composite event. Planned care without acute deterioration and routine consultations do not qualify. Events will be verified from hospital records, authorized external records, and identical follow-up schedules in both groups. Two independent adjudicators blinded to group assignment will review events; a third will resolve disagreements. Death and liver transplantation before a qualifying event will be recorded as competing events. Uncertain event status will not be classified as no event.

Lead sponsor's other trials

Beijing Tsinghua Chang Gung Hospital, most recent start first.